BDBM148356 US10017516, Compound 27::US9682983, 27

SMILES Nc1ccc2c(ccnc2c1)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1

InChI Key InChIKey=UAHBMBZHEHEEAW-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 148356   

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 44nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 44nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 106nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 106nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 140nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 140nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 153nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 153nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 2.60E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 2.60E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 3.40E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148356(US9682983, 27 | US10017516, Compound 27)
Affinity DataIC50: 3.40E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent